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Abstract
Background: Gallbladder carcinoma (GBC) is the most common malignancy of the bile duct and patients with
GBC have extremely poor prognoses. PIK3CA, which encodes the phosphoinositide 3-kinase (PI3K) subunit p110α,
is frequently mutated in many cancers, including GBC. The function of the E545K mutation in GBC is not fully
understood.
Methods: E545K mutation was determined in human GBC tissues by targeted sequencing. The effects of E545K
mutation and PI3K selective inhibitor, A66 on GBC cells were evaluated using Cell Counting Kit-8 (CCK-8) cell
Viability and transwell assays. The mechanisms of E545K mutation and A66 were analyzed by western blot and
co-immunoprecipitation (Co-IP) assay. Subcutaneous xenograft models in nude mice were employed to evaluate
the role of E545K mutation and A66 in GBC progression.
Results: The rate of PIK3CA E545K mutation in GBC patients was 6.15 %. And the survival of GBC patients was
correlated with E545K mutation significantly (P < 0.05). The E545K mutation promoted proliferation, migration and
invasion of GBC cells in vitro and tumor proliferation in vivo. A66 suppressed proliferation of GBC cells in vitro
and tumor proliferation in vivo.
Conclusion: The prognoses of patients with E545K mutation were worse than patients without this mutation.
The E545K mutation promoted GBC progression through enhanced binding to EGFR and activating downstream
akt activity. The PI3K selective inhibitor, A66, suppressed gallbladder carcinoma proliferation.
Keywords: Cancer, PI3K, EGFR, Gallbladder carcinoma
Background
Gallbladder carcinoma (GBC) is the most common ma-
lignancy of the bile duct and the fifth most common
gastrointestinal cancer [1, 2]. Patients with GBC have ex-
tremely poor prognoses, and their 5-year survival rate is
less than 10 % [3, 4]. There is currently no effective drug
for the treatment of patients with GBC, thus, novel effect-
ive drugs are urgently needed to improve the prognoses of
these patients. Precision-medicine has been deemed in-
creasingly important for clinical treatment [5], and the
identification of the mechanisms of the development and
progression of GBC is needed to improve the prognoses
of patients with GBC.
Phosphoinositide 3-kinases (PI3Ks) are key components
of cell signaling pathways that regulate proliferation and
apoptosis and play important roles in the proliferation, in-
vasion and metastasis of cancer cells [6, 7]. Stimulated by
upstream receptor tyrosine kinases (RTKs) and G protein-
coupled receptors (GPCRs), PI3Ks transduce signals into
intracellular messages that then activate AKT and other
downstream effector pathways [8]. Class Ia PI3Ks have
been widely studied and are thought to have the most
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important effects among all PI3Ks [8]. Class Ia PI3Ks con-
tain a p110 catalytic subunit and a p85 regulatory subunit.
Three homologous p110 catalytic isoforms (p110α, p110β
and p110δ) are encoded by three different genes: PIK3CA,
PIK3CB and PIK3CD. The p110α and p110β subunits
are ubiquitously expressed, whereas the p110δ subunit
is largely restricted to the immune system in mammals
[6]. Upon growth factor stimulation, p110α binds to the
phospho-tyrosine residues of receptor protein kinases
or adaptor proteins through interactions with p85 and
subsequently activates the lipid kinase activity of p110α
[9]. Activated p110α converts phosphatidylinositol-4,5-
bisphosphate (PIP2) to phosphatidylinositol-3,4,5-tri-
phosphate (PIP3), and PIP3 subsequently activates the
downstream AKT signaling pathway as a second mes-
senger [9, 10]. Recent cancer studies have revealed that
many components of the PI3Ks, including p110α, are
frequently targeted by germline or somatic mutations
in a variety of human cancers. These findings and the
fact that PI3Ks are highly suited for pharmacologic
intervention make the PI3K pathway one of the most
attractive targets for therapeutic cancer interventions
[11]. Numerous PI3K inhibitors have been tested in
clinical trials in recent years, however, inhibitor resist-
ance has been widely observed [12–15]. Most somatic
PIK3CA mutations in human cancers occur within two
hot spots: E545K and H1047R. The E545K mutation of
PIK3CA was first reported in 2005 [16]. Previous stud-
ies have identified the E545K mutation of PIK3CA in
various carcinomas, including colorectal cancer, glio-
blastoma, gastric cancer, breast cancer, lung cancer
[17], esophageal squamous cell cancer [18], pancreatic
cancer [19], intrahepatic cholangiocarcinoma [20] and
GBC [21]. Recently, we found that E545K is the only
missense mutation of PIK3CA in GBCs based on
whole-exome and targeted genesequencing [21]. The
function of the E545K mutation in GBC cells is not
been fully understood.
In this study, we analyzed the PIK3CA E545K mutation
in a cohort of GBC samples and explored the function of
the PIK3CA E545K mutation in GBC. Moreover, we tested
the effect of a PI3K inhibitor on GBC.
Results
Patients with GBC harboring the E545K mutation exhibit
worse prognoses
In previous work, we found that three of 57 patients
with GBC harbored the PIK3CA E545K mutation [21].
To determine the effect of the E545K mutation, 130 pa-
tients with GBC received follow-up for 36 months after
surgery, and we identified eight patients with the E545K
mutation via targeted sequencing of the resected tumors
(shown in Additional file 1: Table S1). The clinical data
for the patients are provided in Additional file 1: Table S1.
We found that the E545K mutation was not significantly
associated with age, gender, lymph node metastasis,
TNM(tumor, node, metastasis) stage, margin status or
jaundice (Table 1). However, this mutation was signifi-
cantly associated with the patients’ overall survival (Fig. 1).
Thus, we sought to determine the function of the E545K
mutation in GBC.
PIK3CA is vital for the proliferation, migration, invasion
and clone formation of GBC cells in vitro
To investigate the function of PIK3CA in GBC, we
knocked down PIK3CA in GBC cell lines. We assessed
PIK3CA expression in 6 GBC cell lines and found that the
expression quantities in the 6 GBC cell lines were similar
Table 1 Relationships of the PIK3CA E545K mutation with the clinicopathological characteristics of the GBCs
Parameter Category No.of
cases
PI3K E545K mutation status
No.of positive cases (%) χ2 P value
Age <60 60 3 (5 %) 0.020 0.888
≥60 70 5 (7.14 %)
Gender Male 61 3 (4.92 %) 0.034 0.853
Female 69 5 (7.25 %)
Lymph node metastasis Negative 86 4 (4.65 %) 0.373 0.541
Positive 44 4 (9.09 %)
TNM stage II 8 0 (0 %) (a) 0.352
III 101 6 (5.94 %)
IV 21 2 (9.52 %)
Margin status R0 71 5 (7.04 %) 0.009 0.924
R1 59 3 (5.08 %)
Jaundice Negative 91 6 (6.59 %) 0.000 1.000
Positive 39 2 (5.13 %)
(a) The TNM stage data did not meet the criterion for χ2 analysis, thus, we used a Spearman rank correlation analysis
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(Additional file 1: Figure S1a). The GBC-SD and NOZ cell
lines were used in following experiments. Three different
siRNAs were designed to knockdown PIK3CA (Additional
file 1: Figure S1b, c). siRNA2 (referred to as siRNA below)
exhibited the greatest knockdown efficiency and was there-
fore used in the following experiments.
After the knockdown of PIK3CA with siRNA, the pro-
liferations of the GBC-SD and NOZ cells were obviously
suppressed (Fig. 2a, b). Moreover, the knockdown of
PIK3CA significantly suppressed the migration and inva-
sion of GBC-SD and NOZ cells (Fig. 2c-f). We also found
that GBC-SD and NOZ clone formation was suppressed
following the knockdown of PIK3CA (2 g, 2 h). Together,
these findings demonstrated that PIK3CA plays an indis-
pensable role in GBC progression.
The E545K mutation of PIK3CA promotes GBC
progression in vitro
To determine whether the E545K mutation of PIK3CA
affects GBC progression, we transfected PIK3CA-WT
and PIK3CA-E545K plasmids into GBC-SD and NOZ
cells. We conducted reverse transcription polymerase
chain reaction (RT-PCR) and Western blot and observed
similar PI3K p110α expression levels in PIK3CA-E545K
and PIK3CA-WT cells (Additional file 1: Figure S2a-c).
The overexpression of either PIK3CA-WT or PIK3CA-
E545K significantly increased cell proliferation, migration
and invasion in the GBC-SD and NOZ cells (Fig. 3a-f).
Compared with the WT cells, the E545K mutation elicited
greater effects in both the GBC-SD and NOZ cells in terms
of accelerating cells proliferation (Fig. 3a, b). Moreover, the
E545K mutation accelerated cell migration and invasion
more strongly in both the GBC-SD and NOZ cells com-
pared with the WTcells (Fig. 3c-f).
The E545K mutation of PIK3CA increased downstream Akt
activity
We first investigated the proteins in the PI3K-akt
pathway that were functionally associated with cancer
progression. In agreement with the cell proliferation
Fig. 1 Kaplan–Meier curves for the overall survival of GBC patients
according to their wild type (n = 122) or mutation (n = 8)
Fig. 2 PIK3CA is vital for the proliferation, migration, invasion and clone formation of GBC in vitro. a, b GBC-SD and NOZ cells treated with CON,
NC and siRNA were evaluated via a CCK8 cell viability assay. Cell proliferation was represented as cell quantity. Data are presented as mean ± SD
(n = 5). c, d Migration assays of the GBC-SD and NOZ cells treated with CON, NC and siRNA were evaluated with uncoated transwells. Representative
stained images of migrated cells and the numbers of migrated cells (mean ± SD, n = 5) are shown. e, f Invasion assays of the GBC-SD and NOZ cells
treated with CON, NC and siRNA were evaluated with Matrigel-coated transwells. Representative images of stained invaded cells and the numbers of
invaded cells (mean ± SD, n = 5) are shown. g, h GBC-SD and NOZ cells were treated with CON, NC and siRNA and allowed to form colonies.
Representative stained images and the colony numbers (mean ± SD, n = 3) are shown
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experiments, the E545K mutation increased the ex-
pression of cyclin D1 (Fig. 4a, b), which demonstrated
that the E545K mutation promoted the cell cycle and
thus improved cell proliferation. Furthermore the E545K
mutation increased Bcl-2 expression and decreased Bax
expression. The Bcl-2/Bax ratio of the E545K mutants was
significantly greater than that of the WTs (4a, 4c-4e), sug-
gesting that the E545K mutation suppressed cell apoptosis.
We also found that the E545K mutation increased vimen-
tin expression and decreased E-cadherin expression
(Fig. 4a, f and g). These results indicate that the E545K
mutation improved cell migration and invasion, which is
consistent with the observations from the cytological
experiments.
Based on the experiments described above, we found
that E545K-PIK3CA and WT-PIK3CA cells exhibited ab-
normal cytological and protein behaviors. These findings
suggested that the E545K mutation may enhance the ac-
tivity of the PI3K-Akt pathway. Therefore, we investigated
total-Akt and p-Akt expression. As expected, p-Akt ex-
pression in the E545K was higher than WT (Fig. 4h, i),
indicating that the E545K mutation improved Akt activity.
The E545K mutation enhanced the binding of PI3K p110α
to epidermal growth factor receptor (EGFR)
After obtaining the above results, we further sought to
examine how the E545K mutation increased Akt activity.
P110α exerts its effects via recruitment to the membrane
via the interaction of the p85 subunit with the tyrosine
phosphate motifs receptors that are activated in re-
sponse to growth factor stimulation and the subse-
quent activation of RTKs [9, 10]. EGFR is a primary
member of the ERBB family, which is a group of ex-
tremely important RTKs. To explore the potential
mechanism underlying our findings, we hypothesized
that the E545K mutation enhances p110α binding to
EGFRs and subsequently increases PI3K-Akt pathway
activity.
To test this hypothesis, we assessed the amount of
p110α binding to EGFR. After being starved, EGF was
added to GBC-SD and NOZ cells and then cells were
maintained to eliminate other confounding growth fac-
tor signals. We found activated Akt was increasing in
E545K than in WT, although the expression of PI3K
p110α and EGFR was similar in WT and E545K(shown
in Fig. 5a, b). Meanwhile the quantity of PI3K p110α
binding to EGFR in E545K was higher than the quantity
in WT(shown in Fig. 5c, d). This shown E545K enhanced
downstream Akt activity through enhancing PI3K p110α
binding to EGFR.
A selective PI3K p110α inhibitor suppressed GBC
progression in both WT and E545K cells in vitro
Considering the increased activity of Akt in the E545K
compared with WT cells and the worse prognosis of
GBC patients harboring the E545K mutation, we sought
Fig. 3 The E545K mutation of PIK3CA promotes GBC progression in vitro. a, b GBC-SD and NOZ cells treated with CON, WT and E545K were evaluated
using CCK8 cell viability assays. Cell proliferation was represented as cell quantity. Data are presented as mean ± SD (n = 5). c, d Migration assays of the
GBC-SD and NOZ cells treated with CON, WT and E545K were evaluated with uncoated transwells. Representative images of the stained migrated cells
stained pictures and the numbers of migrated cells (mean ± SD, n = 5) are shown. e, f Invasion assays of the GBC-SD and NOZ cells treated with CON,
WT and E545K were evaluated with Matrigel-coated transwells. Representative images of stained invaded cells and the numbers of invaded
cells (mean ± SD, n = 5) are shown
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to determine whether a PI3K inhibitor was effective in
patients with the E545K mutation to satisfy the require-
ment of precision medicine. We selected A66, which is a
widely used selective PI3K p110α inhibitor, to perform
the follow-up experiments. We first measured the half
maximal inhibitory concentration (IC50) of A66 in GBC
cell lines and identified values of 15 μM/L A66 for the
GBC-SD cells and 5 μM/L A66 for the NOZ cells in the
in vitro experiments detailed below (Additional file 1:
Figure S3a, b). IC50 of A66 was from 0.1 to 10 μM/L in
various cells in published literatures [22–24].
We found that A66 not only suppressed the prolifera-
tion of WT GBC-SD and NOZ cells but also significantly
suppressed the proliferation of E545K cells (Fig. 6a-d).
Western blot analyses revealed that A66 significantly sup-
pressed Akt activity in both WT and E545K cells but did
not influence the expression of PI3K p110α (Fig. 6e-h).
We also found that A66 did not influence the binding of
PI3K p110α to EGFR (Fig. 6i, j). These results suggest that
A66 suppressed GBC progression by converting PI3K
p110α into an inactive form but did not down regulate the
expression of PI3K p110α.
Fig. 4 The E545K mutation of PIK3CA increased downstream Akt activity. a-g The functional proteins associated with the PI3K-akt pathway in
cancer progression were examined by Western blot assays. Representative chemiluminescent images and the relative expression quantities
of cyclin D1, bcl-2, Bax, vimentin and E-cadherin (mean ± SD, n = 3) are shown. h, i Key proteins in the PI3K-akt pathway were examined by
Western blot assays. Representative chemiluminescent images of PI3K p110α, p-akt and akt and the relative expression quantities of p-akt
(mean ± SD, n = 3) are shown
Fig. 5 The E545K mutation enhanced PI3K p110α binding to EGFR. a, b After cellular starvation, EGF was added to the GBC-SD and NOZ cells.
EGFR and key proteins in the PI3K-akt pathway were examined by Western blot assays. Representative chemiluminescent images of PI3K p110α,
p-akt, akt and EGFR and the relative expression quantities of p-akt (mean ± SD, n = 3) are shown. c, d PI3K p110α binding to EGFR was examined
by co-immunoprecipitation assays. Representative chemiluminescent images and the relative expression quantities of PI3K p110α binding to EGFR
(mean ± SD, n = 3) are shown
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The E545K mutation promoted GBC progression and the
selective p110α inhibitor suppressed GBC progression in
vivo
We further used a transplantable subcutaneous mouse
tumor model to explore the function of E545K in vivo.
To obtain cell lines that stably expressed WT and
E545K, we selected two cell lines from among 36 differ-
ent monoclonal cells. Similar to the in vitro results, the
E545K and WT lines significantly promoted tumor pro-
liferation compared with the untreated cells (Fig. 7a, b).
Moreover, the proliferation of the E545K line exceeded
that of the WT line in vivo (Fig. 7a, b).
We also tested the effect of the selective PI3K p110α
inhibitor in vivo. Three weeks after the transplantation
of the tumor cells, the mice were injected with 1 mg
A66 every 3 days for 3 weeks. We found that the tumor
volumes and weights of the mice injected with A66 were
obviously reduced compared with mice injected with
normal saline (NS, Fig. 7c). Immunohistochemical stain-
ing for tumors resected from mice treated with A66 or
NS was used to analyze tumor proliferation status. We
found positive ratios of Ki67 in WT and E545K tumors
treated with A66 were higher than in tumors treated
with NS significantly (Fig. 7d, e), and representative pho-
tomicrographs were shown. Furthermore, we found ex-
pression quantity of PI3K p110α in WT and E545K
tumors treated with A66 or NS was similar (Fig. 7d).
These results demonstrate that the selective PI3K p110α
inhibitor significantly suppressed GBC progression fol-
lowing the transplantation of both WT and E545K cells.
Discussion
GBC is a highly fatal disease, thus, the mechanisms of
GBC development and progression require urgent elucida-
tion to identify new early diagnostic methods and novel
drugs to improve the prognoses of patients with GBC
Fig. 6 The selective PI3K p110α inhibitor suppressed GBC progression both in the WT and E545K cells in vitro. a-d After treated with (A66) or
without (CON) 15 μM/L A66 for the GBC-SD cells and 5 μM/L A66 for the NOZ cells, Cell proliferation of WT or E545K GBC-SD and NOZ cells was
evaluated using CCK8 cell viability assays. Cell proliferation was represented as cell quantity. Data are presented as mean ± SD (n = 5). e-h After
treated with (A66) or without (CON) 15 μM/L A66 for the GBC-SD cells and 5 μM/L A66 for the NOZ cells for 24 h, key proteins in PI3K-akt pathway
were examined by Western blot assays. Representative chemiluminescent images of PI3K p110α, p-akt and akt and the relative expression
quantities of p-akt (mean ± SD, n = 3) are shown. i, j PI3K p110α binding to EGFR was examined by co-immunoprecipitation assays. Representative
chemiluminescent images and the relative expression quantities of PI3K p110α binding to EGFR (mean ± SD, n = 3) are shown
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[25, 26]. PI3Ks are widely known to play crucial roles
in both normal cells and cancer cells [6, 7, 27]. Abnor-
mal activation of the PI3K-akt pathway frequently leads
to tumor development and progression [7, 27]. Numerous
PI3K inhibitors have been tested in clinical trials, and in-
hibitor resistance has been observed. Hence, the unknown
mechanism associated with the PI3K-akt pathway has
aroused substantial interest among researchers. The
PIK3CA E545K mutation has been identified in numerous
cancers [17–21].
We followed up 130 patients with GBC for 36 months
after surgery and found that the E545K mutation was as-
sociated with overall survival. The patients with the
E545K mutation had significantly worse prognoses than
the patients without this mutation. We did not identify
any significant associations of the PIK3CA E545K muta-
tion with the clinical data. The possible cause is that the
sample size was not sufficiently large to reveal such
relationships.
The knockdown of PIK3CA significantly suppressed
GBC cell proliferation, migration, invasion and clone
formation, and the overexpression of PIK3CA obviously
promoted these processes in vitro. These findings con-
clusively demonstrated the vital function of PIK3CA in
GBC cells. Compared with the WT PIK3CA, the PIK3CA
with the E545K mutation exhibited stronger effects on cell
proliferation, migration, invasion and clone formation.
Similarly, the E545K mutation exhibited a stronger tumor
Fig. 7 The E545K mutation promoted GBC progression and the selective p110α inhibitor suppressed GBC progression in vivo. a Mice bearing
subcutaneous xenografts of CON, WT and E545K cells were anesthetized and photographed after three weeks. b The tumor volumes of CON, WT
and E545K cell subcutaneous xenografts were measured every three days after inoculation. Data are presented as mean ± SD (n = 5). c Mice
bearing WT and E545K cell subcutaneous xenografts were injected with 1 mg A66 or 100 μl NS every 3 days after inoculation for three weeks.
Tumor volumes were measured every three days. Data are presented as mean ± SD (n = 5). d Representative photomicrographs of
immunohistochemical staining for tumors resected from mice treated with A66 or NS are shown. e Percent of Ki67 positive cells is shown
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proliferation-enhancing effect than the WT in vivo. These
findings are in agreement with discoveries related to other
tumors [8, 28]. We found that the phosphorylated form of
akt was elevated in the E545K mutants compared with the
WTs, but the expression of PIK3CA was similar in the
WT and E545K cells. PI3K p110α (encoded by PIK3CA)
and PI3K p110β (encoded by PIK3CB) play similar roles
in the PI3K-akt pathway, but the activity of p110α is
greater than that of p110β [24]. Therefore, we hypothe-
sized that the E545K mutation could enhance the ability
of p110α to bind to upstream RTKs. We subsequently
quantified the p110α binding to EGFR (which is one of
the most important RTKs) in WT and E545K cell lines
using co-immunoprecipitation (CO-IP). Interestingly, we
observed greater binding of p110α to EGFR in the E545K
cells than in WT cells, although p110α expression was
similar in the WTand E545K cell lines. Together, these re-
sults demonstrated that the E545K mutation of PIK3CA
promotes tumor progression in GBC via enhancement of
the binding to EGFR. The E545K and H1047R mutations
of PIK3CA increase PIP3 levels, activate akt signaling and
induce cellular transformation [7, 29, 30], but the exact
molecular mechanism by which these mutations activate
p110α has not been determined. Some studies have dem-
onstrated that, the regulatory p85 subunit stabilizes the
catalytic p110α subunit and inhibits its enzymatic activity
in the basal state [31]. The p110α subunit contains an N-
terminal adaptor-binding domain, a Ras-binding domain,
a C2 domain, a helical domain, a catalytic domain, more-
over, the helical domain is related to the interaction with
p85 [32]. The mechanism that is currently thought to ex-
plain the oncogenic effect of the E545K mutation is that
the helical domain mutation weakens p110α’s interactions
with the p85 regulatory subunits, which attenuates the in-
hibitory effect of p85 and thus increases the enzymatic ac-
tivity of p110α [33, 34] Moreover, another study suggested
that the weakened p110α-p85 interaction caused by the
mutation is not sufficient for the p110α mutant proteins
to exert their oncogenic functions and provided several
pieces of evidence that the p110α E545K-IRS1 interaction
plays a critical role in tumorigenesis [28]. Our study ad-
vanced the explanation of the oncogenic effect of the
E545K mutation by demonstrating that this mutation pro-
motes tumor progression through enhanced binding to
EGFR in GBC.
Because patients with the E545K mutation have worse
prognoses than those without this mutation, we believe
that the needs of patients with E545K mutation for new
effective drugs is greater than that of patients without
the mutation. Although numerous PI3K inhibitors have
been tested in clinical trials, no drugs are available that
target the E545K mutation. We are convinced that the
efficacy of these drugs should be confirmed in clinical
trials involving patients with the E545K mutation based
on the precision medicine perspective. Some studies
have reported that selective inhibitors may have better
application potentials due to their lower toxicities [8].
Therefore, we tested a selective inhibitor of PI3K p110α
(A66) in vivo and in vitro. Interestingly, we found that
A66 significantly suppressed tumor proliferation in both
WT and E545K cells lines.
In this study, we found that patients with E545K muta-
tion had worse prognoses than those without this muta-
tion and confirmed that the E545K significantly promoted
tumor progression both in vitro and in vivo. Excitingly,
the PI3K inhibitor was effective against the E545K muta-
tion. Considering the lethality of GBCs and highly malig-
nant effect of PIK3CA E545K, we believe that the early
use of effective drugs following gene sequencing may rep-
resent an efficacious method for improving the prognoses
of GBC patients harboring the PIK3CA E545K mutation.
Conclusions
The prognoses of patients with E545K mutation were
worse than patients without this mutation. The E545K
mutation promoted GBC progression through enhanced
binding to EGFR and activating downstream akt activity.




The GBC tissue specimens were obtained from 130 pa-
tients who underwent cholecystectomies from 2008 and
2013 in the Department of General Surgery, Xinhua
Hospital. The sequencing technology was provided by
BioSune (Shanghai, China). The patients follow-ups were
performed via telephone once every three months. This
study was approved by the ethics committee of Xinhua
Hospital, School of Medicine, Shanghai Jiao Tong Univer-
sity. All patients provided written informed consent.
Cell lines and culture
The human gallbladder cancer cell lines GBC-SD, NOZ,
SGC-996, OCUG, EHGB-1 and EHGB-2 were purchased
from Shanghai Institute of Cell Biology, Chinese Academy
of Sciences (CAS, Shanghai, China). The GBC-SD cells
were grown in high-glucose DMEM (Gibco, Grand Island,
NY, USA) supplemented with 10 % fetal bovine serum
(Gibco) and 1 % penicillin-streptomycin(Hyclone, Logan,
UT, USA). The NOZ cells were grown in William’s
medium (Gibco) supplemented with 10 % fetal bovine
serum (Gibco) and 1 % penicillin-streptomycin (Hyclone).
The SGC cells were grown in 1640 medium (Gibco) sup-
plemented with 10 % fetal bovine serum (Gibco) and 1 %
penicillin-streptomycin (Hyclone), The OCUG, EHGB-1
and EHGB-2 cells were grown in high-glucose DMEM
(Gibco) supplemented with 15 % fetal bovine serum
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(Gibco) and 1 % penicillin-streptomycin (Hyclone). All cells
lines were maintained at 37 °C in a humidified atmosphere
with 5 % CO2. The A66 used in the in vitro and in vivo ex-
periments was purchased from Selleck Chemicals (Hous-
ton, USA). Before conducting the CO-IP experiments, the
GBC-SD and NOZ cells were starved for 12 h and 1 ng/mL
EGF (Sangon Biotech, Shanghai, China) was added to the
cell culture medium. The cells were maintained for 12 h to
eliminate other confounding growth factor signals.
RT-PCR, Q-PCR and sequencing
Total RNA was extracted from the cultured GBC-SD,
NOZ, SGC-996, OCUG, EHGB-1, and EHGB-2 cells or
tissue samples with Trizol reagent (Takara, Shiga, Japan).
cDNA was synthesized from 1 μg of total RNA using
random primers and M-MLV Reverse Transcriptase
(Takara). The RNA expression quantities were measured by
RT-PCR using the SYBR-Green method (Takara) on a Ste-
pOnePlus system (Thermo Fisher Scientific, USA) accord-
ing to the manufacturer’s instructions. The relative
expression levels of the target genes were calculated by as
2-ΔCT (ΔCT=CT
PIK3CA -CT
GADPH) and normalized to the
relative expressions detected in the corresponding control
cells, which were defined as 1.0. In the present study, the
expression levels (defined as the fold changes) of PIK3CA
were calculated as 2-ΔΔCT(ΔΔCT=ΔCTsample1-ΔCTsample2).
The sequencing service was provided by BioSune
(Shanghai, China).
The RT-PCR primer sequences were as follows:
F-primer: 5′-AGAAGATTTGCTGAACCCTATTGG-3′
R-primer: 5′-CACTGACATATCTGGGAACTTTACC-3′
The sequencing Primer sequences were as follows:
F-primer: 5′-ATACATCTGGGCTACTTC-3′
R-primer: 5′-ACCCTATTGGTGTTACTG-3′
Cell transfections with siRNA or plasmid
The siRNAs were synthesized by Biomics (Nantong, China).
The siRNA sequences were as follows:












The PIK3CA-WT(wile-type) plasmid and the PIK3CA-
E545K mutation plasmid were gifts from Bert Vogelstein
[17] (Addgene plasmid #16643 and #16642, respectively).
siRNA or plasmids were transfected into the cells using
Lipofectamine 2000 (Thermo Fisher Scientific) according
to the manufacturer’s instructions.
Western blot and Co-IP analyses
The GBC-SD and NOZ cells were collected with the cul-
ture medium into centrifuge tubes. After centrifugation
at 1500 r/min for 3 min, the cells were washed twice
with cold phosphate-buffered saline (PBS). Then, the
cells were lysed with RIPA buffer (Beyotime Institute of
Biotechnology, Beijing, China) and protease inhibitor
(Roche Applied Science, Indianapolis, IN, USA) at 4 °C
for 5 min. After centrifugation at 14,000 r/min at 4 °C
for 5 min, the protein concentration was measured using
a bicinchoninic acid (BCA) assay kit (Beyotime, Shanghai,
China). Equal amounts of protein (40 μg/lane) from the
different samples were separated by 10 % sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and then electrophoretically transferred to nitrocellulose
membranes (Millipore, Bedford, MA, USA). The mem-
branes were blocked with 5 % skim milk for 2 h and
then incubated with the primary antibodies against
PI3K p110α (CST, Cell Signaling Technology, USA),
Bcl-2(Proteintech), Bax(Proteintech), cyclin D1(Pro-
teintech), β-actin(Proteintech), vimentin(Proteintech),
E-cadherin(Proteintech), Akt and P-akt (Proteintech)
(1:1000) at 4 °C overnight. The membranes were incubated
with the secondary antibodies (horseradish peroxidase
HRP-conjugated goat anti-rabbit/anti-mouse IgG 1:5000;
Abcam, Cambridge, UK) for 2 h after washing three times
with TBST buffer. The bands were visualized using a
chemiluminescent detection kit (Rockford, IL, USA) and
photographed using a Gel Doc 2000 (BioRad, Hercules,CA,
USA). The immunoprecipitations were set up as follows:
Lysates containing 0.5 mg of total protein were incubated
with 1 1 μL of EGFR antibody(CST). All immunoprecipita-
tions were performed overnight, and protein A/G seph-
arose (Santa Cruz Biotechnology) was added for 2 h.
The beads were then collected by centrifugation at
1000 r/min, followed by three washes with lysis buffer.
The resulting immunoprecipitates were subjected to
Western blot analyses.
Cell proliferation assay
The proliferations of the GBC-SD and NOZ cells lines
treated with siRNA, negative control (NC) siRNA (random
null siRNA sequence), CON (only Lipofectamine 2000),
WT (PIK3CA-WT plasmid), E545K (PIK3CA-E545K plas-
mid) and vector (empty vector) were measured using a Cell
Counting Kit-8 (CCK8, Dojindo, Japan) assay according to
the manufacturer’s instructions. The GBC-SD (8 × 104)
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and NOZ (5 × 104) cells were seeded into 6-well plates
(Corning, NY, USA) and incubated overnight. The cells
were then transfected with siRNA, NC, CON, WT,
E545K or vector. The cells were maintained for 12 h
and then seeded into 96-well plates (500 cells in each
well). The cells were maintained for 6, 24, 48, 72, 96 and
120 h, and CCK-8 was then added to each well, and cells
were incubated at 37 °C for 3 h. The optical densities
(ODs) were measured at a wavelength of 450 nm with a
microplate reader (QuantBio Tek Instruments, Winooski,
VT, USA). The results are represented as averages of
five different wells. Cell proliferation was measured ac-
cording to the following the formula: cell proliferation =
(ODDay n/ODDay1)*100 %.
Cell migration and invasion assays
Cell migration and invasion were examined using trans-
well filters (BD Biosciences, Franklin Lakes, NJ). GBC-
SD and NOZ cells were treated with siRNA, NC, CON,
WT, E545K or vector same as described above. GBC-SD
(2 × 104) and NOZ (1.5 × 104) cells in 200 μL serum-free
DMED medium or William’s medium were added to the
upper chamber, which contained an uncoated or Matri-
gel (BD Biosciences)-coated membrane. The lower
chamber was filled with 500 μL of basal medium with
10 % fetal bovine serum. After incubation at 37 °C in a
humidified 5 % CO2 incubator for 18 h for the siRNA
knockdown experiments or 12 h for the plasmid overex-
pression experiments in the uncoated transwells and
24 h for the siRNA knockdown experiments or 18 h for
the plasmid overexpression experiments in the Matrigel-
coated transwells, the cells that migrated to the lower
compartment were fixed with 4 % paraformaldehyde for
20 min and stained with 0.1 % crystal violet (Sigma-
Aldrich) for 30 min. The migrated or invaded cells
were counted in five fields (above, below, left, right
and middle of the well) in each well. Imaging and cell
counting were performed under a microscope (Leica,
Wetzlar, Germany).
Colony formation assay
GBC-SD and NOZ cells were treated with siRNA, NC,
CON, WT, E545K or vector as what described above.
The cells were dispersed as single cell suspensions, and
500 cells per well were planted into 6-well plates. The
cells were cultured (5 days for the NOZ cells and 14 days
for the GBC-SD cells) to allow for colony formation.
Subsequently, the cells were fixed with 4 % paraformal-
dehyde for 20 min and stained with 0.1 % crystal violet
for 30 min. The plates were air-dried after washing and
the stained colonies were photographed using a micro-
scope. The total number of colonies (>50 cells/colony)
was counted.
Screening of the stable expression cell lines
The PIK3CA-WT and PIK3CA-E545K mutation plasmids
were transfected into NOZ cells with Lipofectamine 2000
(Thermo Fisher Scientific). Cell culture medium with
1000 μg/mL G418 was added and then replaced with fresh
culture medium with 500 μg/mL G418 every three days.
The cells were cultured for two weeks at 37 °C in a humidi-
fied atmosphere with 5 % CO2. The cells were diluted to
single cells and planted into 96-well plates. Monoclones
were selected for amplification and then assessed by West-
ern blot assays using anti-flag antibody (Sigma-Aldrich,
USA).
In vivo subcutaneous xenograft analysis
The animal use and the experiment protocol were ap-
proved by the Institutional Animal Care and Use Commit-
tee of Xinhua Hospital, School of Medicine, Shanghai Jiao
Tong University. Subcutaneous xenograft models were
established as previously described [35]. Nude mice were
randomly divided into control, WT and E545K mutation
groups that received subcutaneous injection inoculations
with 1 × 106 NOZ, NOZ-WT and NOZ-E545K cells, re-
spectively. The tumor volumes were measured using
Vernier calipers once every three days, and the tumor vol-
umes were calculated according to the following formula:
tumor volume (mm3) = L ×W2 (where L and W represent
the length and width of the tumor, respectively). On day
21, the mice were anesthetized and photographed. After-
wards, the mice in the control group were sacrificed. The
WT group and the E545K mutation group were randomly
divided into A66 group and normal saline groups. The
mice in the A66 group were injected with 1 mg A66 once
every three days through the tail vein for three weeks, and
the mice in normal saline group were injected with same
volume of normal saline. The tumor volumes were mea-
sured once every three days as previously described. On
day 42, the mice were sacrificed, and the tumor tissues
were removed and weighed.
Immunohistochemistry(IHC) assays
Three weeks after treated with A66 or NS, the mice
were sacrificed and the tumors were dissected out. The
PI3K p110α expression and proliferative index of Ki-67 was
evaluated in xenograft tumors by immunohistochemical
staining (IHC). IHC staning was performed as previously
described [2].
Statistical analysis
SPSS 18.0 software was used to perform the statistical
analyses. All values are expressed as the mean ± the
standard deviation (SD) unless otherwise stated. Student’s
t-tests were performed to compare the differences be-
tween the different experiment groups unless otherwise
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stated. P-values less than 0.05 were considered statistically
significant (P < 0.05 is denoted by *).
Additional file
Additional file 1: Table S1. The clinical data for the patients in the
study. Figure S1. (a) Expression of PIK3CA in NOZ, GBC-SD, SGC-996,
OCUG, EHGB-1 and EHGB-2 cell lines was measured by RT-PCR. Relative
expression quantity was shown(mean ± SD, n = 5). (b, c) Three different
siRNAs werer designed to knock down PIK3CA in GBC-SD and NOZ.
Expression of PIK3CA was measured by RT-PCR. Relative expression
quantity was shown(mean ± SD, n = 5). Figure S2. (a) RT-PCR was used to
measure the relative expression of PIK3CA of GBC-SD and NOZ after be
transfected with WT and E545K plasmid. Data are presented as mean ± SD
(n = 5). (b, c) Expression of PI3K p110α was examined by Western-Blot assay.
Representative chemiluminescent images and the relative expression
quantity (mean ± SD, n = 3). Figure S3. (a, b) GBC-SD and NOZ cells treated
with different concentration of A66 were evaluated by CCK8 cell viability
assay for 3 days. Data are presented as mean ± SD (n = 5). (DOCX 482 kb)
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